(7) Alignment and updating (the discipline of time) | JPMA Guide Commentary | Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence

A material begins to go out of date the moment it is printed. Drug information keeps moving after approval. When re-examination or re-evaluation results are published, the package insert is rewritten; when post-marketing surveillance identifies a new adverse reaction, a warning is added. Because a Product Information Summary transcribes information as of a particular point in time, that "point in time" is constantly under pressure to be updated.

Items (17) through (20) of Chapter 1, Section 1 address this problem of time directly. Consistency with conditions and instructions at approval, synchronization with the latest official materials, the promptness of revision, and compliance with overarching regulations — these four requirements may look independent, but together they support, from the operational side, the verifiability that the foreword puts forward: keeping the material in a state where its point in time can be traced after the fact.

The relationship the foreword sets out — "the package insert is the original; the summary merely supplements it" — must hold along the time axis as well. When the original is updated, the supplement follows. Until it can follow, the gap must be made visible enough for readers to verify it for themselves. That is the rationale for alignment and updating.

01Consistency with conditions at approval — fixing the starting point

For new drugs, a substantial body of discussion accumulates during the approval review. The record of deliberations at the Pharmaceutical Affairs and Food Sanitation Council captures both the reasoning behind the evaluation of efficacy and safety and any conditions or instructions that followed from it. A Product Information Summary must be written with "full consideration" of those deliberations.

"Full consideration" sounds abstract, but the substance is concrete. When conditions or instructions were attached at approval — for example, that use in a specific patient group be confirmed first, or that a certain test be performed before starting treatment — the material must be prepared in a way that maintains consistency with the relevant items. Any section of the material that touches on those conditions may not minimize them or render them less visible.

Why return to the time of approval? Approval conditions are the outcome of deliberation that concluded: "This drug requires this brake." Writing without that foundation allows the weight of the information reaching healthcare professionals to diverge from what deliberation actually established. The foreword's "inform accurately without misleading" means accuracy that encompasses conditions and constraints.

02Synchronization with official materials — aligning three windows with the latest version

When preparing or revising a material, consistency must be maintained with the latest package insert, review report, and re-examination and re-evaluation results.

Package insert: the original that keeps being updated

The package insert is the legally authoritative source of drug information, and the latest version is published with each revision. The window that the Product Information Summary holds open looks onto this package insert. In Chapter 2 as well, the Product Information (DI) section is written in accordance with the latest package insert, with its date of preparation or revision noted. Declaring the version lets the reader verify "as of when did this material consult the package insert." Checking alignment starts with comparing versions.

Review report: the published record of the basis for approval

The review report is a public document that shows how the regulatory authority evaluated efficacy and safety during the approval review. It serves as a reference point for confirming that what the material states is not at odds with the facts confirmed during review. The sections that allow narrative — development history, features — are particularly prone to letting claims slip in that diverge from the context of the review.

Re-examination and re-evaluation results: the evaluation that continues to be updated after approval

A drug continues to be evaluated after approval through post-marketing surveillance, use-result surveys, and adverse reaction reporting. When re-examination or re-evaluation results are finalized, they become the latest official evaluation and lead to revisions of the package insert. The requirement to maintain alignment asks that materials follow this continuously moving cycle of evaluation.

The three official materials serve different roles. The package insert is "current approved information"; the review report is "the reasoning that led to approval"; re-examination and re-evaluation results are "updated post-marketing evaluation." When a material is consistent with all three, readers know exactly where to go to return to the primary source. That is the operational form of verifiability.

03Prompt revision — the danger that time gaps create

When the items that warrant particular attention within indications and dosage, dosage and administration, and precautions including warnings and contraindications are revised, the Product Information Summary must be revised promptly.

Consider what "promptly" means through the lens of information asymmetry. Even after the package insert is revised, as long as the old material continues in circulation, the information in the hands of healthcare professionals diverges from the actual approved content. That time gap is most serious when the revision concerns safety — a new warning added, a contraindication changed, a serious adverse reaction recorded.

Requiring prompt revision for "items that warrant particular attention" clarifies the operational priority. The obligation is not to process every revision at the same speed, but to reflect changes with direct safety implications first. Stated the other way: the requirement makes explicit that revisions to warnings and contraindications rank above minor wording edits in urgency.

Even when there is not enough time to recall and replace the old material, the requirement includes advancing preparation of the revised version and making it ready for distribution. Promptness means the speed of starting a revision, not only the speed of completing one.

04Compliance with overarching regulations — sharing the ceiling of rules

Compliance is required with relevant laws and regulations, including the Act on the Assurance of Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products and Cosmetics (the Pharmaceuticals and Medical Devices Act) and the Standards for Fair Advertising, as well as voluntary standards including the JPMA Code and JPMA notifications.

The two-tier structure of law and voluntary norms

The PMD Act and the Standards for Fair Advertising draw the legal ceiling. Below them, the JPMA Code and JPMA notifications are the behavioral norms the industry has set for itself. The Preparation Guide operates as the individual implementation rules below both tiers. It follows that even where the Guide is silent, the law and voluntary norms provide the direction for a judgment.

The four conditions in this group — consistency with approval conditions (17), synchronization with official materials (18), prompt revision (19), compliance with overarching regulations (20) — approach the same underlying problem from different angles. Is the information from the right point in time? Does it match the official evaluation? Has it followed changes? Does it stay within the regulatory framework? Maintaining alignment on both the time axis and the normative axis — that is the common requirement of (17) through (20).

05Connection to the foreword's three pillars

The alignment and updating group implements the foreword's three pillars — verifiability, accuracy, and transparency — along the dimension of time.

Foreword pillar	How it appears in the alignment and updating group
Verifiability	Referencing the package insert version, review report, and re-examination results lets readers trace after the fact which evaluation the material was based on
Accuracy	Consistency with approval conditions and instructions, and prompt revision, maintain a state where the material does not diverge from the current approved content
Transparency	Explicit compliance with overarching regulations lets readers know the standards to which the material is held

The nature of a material — that it begins to go out of date the moment it is printed — cannot be changed. That is precisely why declaring the version, synchronizing with official materials, following safety revisions without delay, and remaining within the regulatory framework matter. By holding to these four points, a material that is only a snapshot of one moment can maintain its trustworthiness as a verifiable record.

In closing

Items (17) through (20) ask that a material always be in a position to answer: "as of when is this information?" and "what is it prepared in accordance with?" Embedding the conditions set at approval, synchronizing with three official materials, following safety revisions promptly, and staying within the law and voluntary norms — these are not separate obligations. They are a single, connected discipline for keeping a material honest as time passes.

When the discipline of alignment and updating is upheld, a Product Information Summary can make a promise to the reader: "this version accurately reflects the official evaluation as of this date." That promise supports the judgment of the healthcare professional who picks up the material in the next encounter.

Case studies — the "it isn't written, so…" mindset, and how each lands

A material begins to age the moment it is printed. Each movement in an approved condition, a public document, or a safety notice widens the gap. The four levels show how the obligations to "align promptly" and "keep in sync" break down along the time axis.

GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)

The scheme: "The package insert was revised, but the change added an item to 'Important precautions,' not to 'Warnings' or 'Contraindications.' That is not a revision to 'matters requiring particular attention,' so we scheduled the material update for the next scheduled redesign in six months."

Verdict: "Matters requiring particular attention" can include additions to Important Precautions. The sync obligation also applies continuously — the material must remain aligned with the current package insert at all times, not only when warnings or contraindications change. Continuing to distribute an outdated version until the next redesign violates that spirit.

GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)

The scheme: "The package insert version number in the material was updated after revision. The revised insert added an approval condition, but only the version number was changed; the new condition was not stated in the material. Physicians can check the insert itself."

Verdict: Updating the version number is the starting point of alignment, not evidence of it. If a condition added in the revised insert does not appear in the material's text, the content is out of date regardless of the correct version stamp. A structure where readers must cross-reference the full insert to discover the discrepancy preserves verifiability only in form.

GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)

The scheme: "The review report flagged that data in a specific patient subgroup were limited. The 'Development Background' section of the material presents trial results as broadly applicable, without mentioning that limitation. We are required to consult the review report, but its content does not dictate what we write."

Verdict: The provision requires that approval conditions and points raised in the review process be "given full consideration." Presenting trial results as broadly applicable while omitting a regulatory limitation explicitly noted in the review report constitutes a representation that the efficacy is better than actually demonstrated — prohibited under the Fair Advertising Standards regardless of what the provision specifies.

BLACK — Breaching the explicit text (a plain violation of the provision itself)

The scheme: "A warning was added in a package insert revision. We were aware internally, but cost and timing made it impractical to revise the material immediately, so the old version continued to be distributed for three months. The updated insert is publicly available for any physician who checks."

Verdict: A warning addition is the clearest example of a matter requiring prompt revision, and the obligation is stated in plain text. Cost and timing are not grounds for delay. If an adverse event covered by the warning occurs while the outdated material is in distribution, the explicit breach is directly linked to a concrete harm risk. Revision must begin immediately, and distribution of the old version must stop or be replaced.

Improper intent by implication — three scopes of "insinuating" without stating it

The currency and consistency requirement is not "do not use old data" but "do not conceal change." Through retaining pre-revision data, deferring new information, and marginalising revision content, an unfavourable update can be made effectively invisible.

Implication 1 — Local: carried in a single word or sentence

How it is built: A package-insert revision changed the efficacy statement from "efficacy is established" to "efficacy is recognised (limited to certain patient subgroups)." The material uses the phrase "substantial efficacy has been demonstrated" — a near-equivalent of the pre-revision wording — without mentioning the subgroup restriction added by the revision.

Intent that can be read: The patient-subgroup restriction introduced by the revision is not absorbed into the material; the wording chosen implies broader applicability than the updated package insert allows.

Verdict: Revisions to the package insert must be reflected promptly in every corresponding section of the material. Continuing to use language that does not incorporate the restrictions added by a revision amounts to deliberately maintaining a state of non-synchronisation with the current official source.

Implication 2 — Adjacent: read across neighboring clauses

How it is built: A sentence reads "Pre-revision data are also included as reference values demonstrating continued utility," followed immediately by a table of pre-revision efficacy figures showing a higher responder rate than the current approved data. The current (post-revision) figures appear in the next paragraph as a separate table.

Intent that can be read: The pre-revision table, introduced as "reference," is what the reader encounters first; the higher figures form the initial numerical impression. The post-revision numbers are processed as supplementary information arriving afterwards. The order of impression formation is engineered.

Verdict: The current post-revision figures are primary and should be presented first; pre-revision data should follow as a historical "reference." The reverse order — old data first, new data second — deliberately directs the reader's first numerical impression toward the pre-revision values. When a revision exists, the current official data leads; pre-revision data, if included at all, is placed after and clearly labelled as such.

Implication 3 — Whole-context: arising from the document as a whole

How it is built: A package-insert revision added a new precaution for use in patients with specific degrees of renal impairment. This precaution appears only in the "Revision History" table on the final page of the material. The safety and dosing sections in the body of the material retain pre-revision descriptions unchanged.

Intent that can be read: In the sections prescribers actually consult — dosing guidance, safety summary — the pre-revision safety profile remains intact. The new precaution exists only as an archived record. A reader using the material in the normal way is unlikely to notice the new requirement.

Verdict: A safety revision must be reflected not only in a revision-history log but promptly in each relevant body-text section — the safety section, precaution statements, and descriptions of the affected patient population. A revision log is a record of change; it is not a substitute for updating the body text.